These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24833869)

  • 1. Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
    Kang BW; Kim JG; Kwon OK; Chung HY; Yu W
    World J Gastroenterol; 2014 May; 20(18):5396-402. PubMed ID: 24833869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
    Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
    Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
    Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
    J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
    Park SH; Choi EY; Bang SM; Cho EK; Lee JH; Shin DB; Ki Lee W; Chung M
    Anticancer Drugs; 2005 Jul; 16(6):621-5. PubMed ID: 15930889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.
    Shitara K; Matsuo K; Mizota A; Kondo C; Nomura M; Takahari D; Yokota T; Ura T; Ito S; Sawaki A; Tajika M; Kawai H; Muro K
    Gastric Cancer; 2011 Jun; 14(2):155-60. PubMed ID: 21340668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
    Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for advanced gastric cancer.
    Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
    Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
    Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
    Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
    Park SH; Nam E; Park J; Cho EK; Shin DB; Lee JH; Lee WK; Chung M; Lee SI
    Ann Oncol; 2008 Apr; 19(4):729-33. PubMed ID: 18083691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
    Bozkurt M; Amlashi FG; Blum Murphy M
    Minerva Chir; 2017 Aug; 72(4):317-333. PubMed ID: 28415835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line chemotherapy for advanced gastric cancer in Korea.
    Baek SK; Kim SY; Jeong JH; Cho KS; Yoon HJ
    Gastric Cancer; 2012 Oct; 15(4):345-54. PubMed ID: 22410800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
    Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
    Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan in the treatment of gastric cancer.
    Bugat R
    Ann Oncol; 2003; 14 Suppl 2():ii37-40. PubMed ID: 12810456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.
    Moehler M; Haas U; Siebler J; Schimanski C; Hertkorn C; Hoehler T; Galle PR; Heike M
    Anticancer Drugs; 2003 Sep; 14(8):645-50. PubMed ID: 14501387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical development of chemotherapy for advanced gastric cancer].
    Sato A; Matsukawa M
    Nihon Shokakibyo Gakkai Zasshi; 2007 Feb; 104(2):186-93. PubMed ID: 17283412
    [No Abstract]   [Full Text] [Related]  

  • 17. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
    Roy A; Cunningham D; Hawkins R; Sörbye H; Adenis A; Barcelo JR; Lopez-Vivanco G; Adler G; Canon JL; Lofts F; Castanon C; Fonseca E; Rixe O; Aparicio J; Cassinello J; Nicolson M; Mousseau M; Schalhorn A; D'Hondt L; Kerger J; Hossfeld DK; Garcia Giron C; Rodriguez R; Schoffski P; Misset JL
    Br J Cancer; 2012 Jul; 107(3):435-41. PubMed ID: 22767144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
    Luo HY; Wang ZQ; Wang FH; Qiu MZ; Teng KY; Ruan DY; He YJ; Li YH; Xu RH
    Am J Clin Oncol; 2011 Dec; 34(6):555-60. PubMed ID: 22101386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in chemotherapy for advanced gastric cancer].
    Xu RH; Teng KY
    Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.